China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide drug, has been approved in China for a clinical study in COVID-19 infection.
Drug Mechanism and Development
The Category 1 drug candidate, co-developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences, can play an antiviral role by inhibiting the two membrane fusion pathways of cell surface and endosome. Youcare Pharma owns all global exclusive rights to the drug.-Fineline Info & Tech
